32 results on '"Maria J. Merino"'
Search Results
2. Deep learning‐based decision forest for hereditary clear cell renal cell carcinoma segmentation on MRI
- Author
-
Nathan Lay, Pouria Yazdian Anari, Aditi Chaurasia, Fatemeh Dehghani Firouzabadi, Stephanie Harmon, Evrim Turkbey, Rabindra Gautam, Safa Samimi, Maria J. Merino, Mark W. Ball, William Marston Linehan, Baris Turkbey, and Ashkan A. Malayeri
- Subjects
General Medicine - Published
- 2023
3. Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines
- Author
-
Young H. Lee, Adam R. Metwalli, Darawalee Wangsa, Darmood Wei, Hesed Padilla-Nash, Martin Lang, Maria J. Merino, Thomas Ried, Cathy D. Vocke, Ramaprasad Srinivasan, Paul S. Meltzer, Carole Sourbier, Youfeng Yang, W. Marston Linehan, J. Keith Killian, Mark W. Ball, and Christopher J. Ricketts
- Subjects
Cancer Research ,papillary renal cell carcinoma ,Biology ,medicine.disease_cause ,pRCC ,CDKN2A ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Type 1 Papillary Renal Cell Carcinoma ,Renal cell carcinoma ,Cell Line, Tumor ,Chromosomal Instability ,Genetics ,medicine ,Animals ,Humans ,hereditary type 1 papillary renal cell carcinoma ,Carcinoma, Renal Cell ,Research Articles ,Cyclin-Dependent Kinase Inhibitor p16 ,Chromosome 7 (human) ,Mutation ,Papillary renal cell carcinomas ,cell line ,Proto-Oncogene Proteins c-met ,medicine.disease ,Xenograft Model Antitumor Assays ,Kidney Neoplasms ,Cell Line Authentication ,Cell culture ,030220 oncology & carcinogenesis ,MET ,Cancer research ,Clear cell ,Research Article - Abstract
Renal cell carcinoma (RCC) is not a single disease but is made up of several different histologically defined subtypes that are associated with distinct genetic alterations which require subtype specific management and treatment. Papillary renal cell carcinoma (pRCC) is the second most common subtype after conventional/clear cell RCC (ccRCC), representing ~20% of cases, and is subcategorized into type 1 and type 2 pRCC. It is important for preclinical studies to have cell lines that accurately represent each specific RCC subtype. This study characterizes seven cell lines derived from both primary and metastatic sites of type 1 pRCC, including the first cell line derived from a hereditary papillary renal carcinoma (HPRC)‐associated tumor. Complete or partial gain of chromosome 7 was observed in all cell lines and other common gains of chromosomes 16, 17, or 20 were seen in several cell lines. Activating mutations of MET were present in three cell lines that all demonstrated increased MET phosphorylation in response to HGF and abrogation of MET phosphorylation in response to MET inhibitors. CDKN2A loss due to mutation or gene deletion, associated with poor outcomes in type 1 pRCC patients, was observed in all cell line models. Six cell lines formed tumor xenografts in athymic nude mice and thus provide in vivo models of type 1 pRCC. These type 1 pRCC cell lines provide a comprehensive representation of the genetic alterations associated with pRCC that will give insight into the biology of this disease and be ideal preclinical models for therapeutic studies.
- Published
- 2021
4. Deep‐Learning‐Based Artificial Intelligence for <scp>PI‐RADS</scp> Classification to Assist Multiparametric Prostate <scp>MRI</scp> Interpretation: A Development Study
- Author
-
Jonathan Sackett, Peter L. Choyke, Baris Turkbey, Stephanie Harmon, Peter A. Pinto, Thomas Sanford, Sena Tuncer, Evrim B. Turkbey, Maria J. Merino, Christopher Yang, Manuel Madariaga, Sheng Xu, Bradford J. Wood, Deepak Kesani, Pingkun Yan, and Sherif Mehralivand
- Subjects
Male ,Population ,Wald test ,Article ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,Deep Learning ,0302 clinical medicine ,Artificial Intelligence ,Prostate ,Biopsy ,medicine ,Humans ,Effective diffusion coefficient ,Radiology, Nuclear Medicine and imaging ,Multiparametric Magnetic Resonance Imaging ,Stage (cooking) ,education ,Retrospective Studies ,education.field_of_study ,medicine.diagnostic_test ,business.industry ,Prostatic Neoplasms ,Retrospective cohort study ,Magnetic Resonance Imaging ,PI-RADS ,medicine.anatomical_structure ,Artificial intelligence ,business - Abstract
BACKGROUND: The Prostate Imaging Reporting and Data System (PI-RADS) provides guidelines for risk stratification of lesions detected on multiparametric MRI (mpMRI) of the prostate but suffers from high intra/interreader variability. PURPOSE: To develop an artificial intelligence (AI) solution for PI-RADS classification and compare its performance with an expert radiologist using targeted biopsy results. STUDY TYPE: Retrospective study including data from our institution and the publicly available ProstateX dataset. POPULATION: In all, 687 patients who underwent mpMRI of the prostate and had one or more detectable lesions (PI-RADS score >1) according to PI-RADSv2. FIELD STRENGTH/SEQUENCE: T(2)-weighted, diffusion-weighted imaging (DWI; five evenly spaced b values between b = 0–750 s/mm(2)) for apparent diffusion coefficient (ADC) mapping, high b-value DWI (b = 1500 or 2000 s/mm(2)), and dynamic contrast-enhanced T(1)-weighted series were obtained at 3.0T. ASSESSMENT: PI-RADS lesions were segmented by a radiologist. Bounding boxes around the T(2)/ADC/high-b value segmentations were stacked and saved as JPEGs. These images were used to train a convolutional neural network (CNN). The PI-RADS scores obtained by the CNN were compared with radiologist scores. The cancer detection rate was measured from a subset of patients who underwent biopsy. STATISTICAL TESTS: Agreement between the AI and the radiologist-driven PI-RADS scores was assessed using a kappa score, and differences between categorical variables were assessed with a Wald test. RESULTS: For the 1034 detection lesions, the kappa score for the AI system vs. the expert radiologist was moderate, at 0.40. However, there was no significant difference in the rates of detection of clinically significant cancer for any PI-RADS score in 86 patients undergoing targeted biopsy (P = 0.4–0.6). DATA CONCLUSION: We developed an AI system for assignment of a PI-RADS score on segmented lesions on mpMRI with moderate agreement with an expert radiologist and a similar ability to detect clinically significant cancer. LEVEL OF EVIDENCE: 4 TECHNICAL EFFICACY STAGE: 2204
- Published
- 2020
5. Germline mutations of renal cancer predisposition genes and clinical relevance in Chinese patients with sporadic, early‐onset disease
- Author
-
Junlong Wu, Dingwei Ye, Hongkai Wang, Hailiang Zhang, Guohai Shi, Maria J. Merino, Yao Zhu, Youfeng Yang, W. Marston Linehan, Christopher J. Ricketts, and Hualei Gan
- Subjects
Adult ,Male ,Cancer Research ,Adolescent ,Angiomyolipoma ,Disease ,Article ,Tuberous Sclerosis Complex 1 Protein ,Germline ,Fumarate Hydratase ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Germline mutation ,Asian People ,Tuberous Sclerosis Complex 2 Protein ,Humans ,Medicine ,Genetic Predisposition to Disease ,Clinical significance ,030212 general & internal medicine ,Family history ,Carcinoma, Renal Cell ,Gene ,Cyclin-Dependent Kinase Inhibitor p16 ,Germ-Line Mutation ,BRCA2 Protein ,Genetics ,BAP1 ,business.industry ,Tumor Suppressor Proteins ,High-Throughput Nucleotide Sequencing ,Sequence Analysis, DNA ,Kidney Neoplasms ,Oncology ,030220 oncology & carcinogenesis ,Female ,Personalized medicine ,business ,Ubiquitin Thiolesterase - Abstract
BACKGROUND: An inherited susceptibility to renal cancers is associated with multiple predisposing genes, but most screening tests are limited to patients with a family history. Next-generation sequencing (NGS)–based multigene panels provide an efficient and adaptable tool for investigating pathogenic germline mutations on a larger scale. This study investigated the frequency of pathogenic germline mutations in renal cancer predisposition genes in patients with sporadic, early-onset disease. METHODS: An NGS-based panel of 23 known and potential renal cancer predisposition genes was used to analyze germline mutations in 190 unrelated Chinese patients under the age of 45 years who presented with renal tumors. The detected variants were filtered for pathogenicity, and then their frequencies were calculated and correlated with clinical features. Germline variants of the fumarate hydratase (FH) and BRCA1-associated protein 1 (BAP1) genes were comprehensively analyzed because of their aggressive potential. RESULTS: In total, 18 patients (9.5%) had germline mutations in 10 genes. Twelve of these 18 patients had alterations in renal cancer predisposition genes (6.3%), and 6 patients had mutations in potential predisposition genes such as BRCA1/2. Notably, pathogenic mutation carriers had a significant family history in second-degree relatives in comparison with those without pathogenic mutations (P < .001). Variants of unknown clinical significance in FH and BAP1 demonstrated evidence of additional somatic loss in tumors CONCLUSIONS: In patients with early-onset disease, a multigene panel identified a high pathogenic germline mutation rate in renal cancer predisposition genes. This study emphasizes the importance of screening patients with early-onset disease for mutations in cancer predisposition genes. Germline screening should be encouraged in early-onset patients to provide personalized medicine and improve patient outcomes.
- Published
- 2018
6. TheFOXA2transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas
- Author
-
Matthieu Le Gallo, Nancy F. Hansen, Meghan L. Rudd, Daphne W. Bell, James C. Mullikin, Maria J. Merino, David G. Mutch, Mary Ellen Urick, and Paul J. Goodfellow
- Subjects
0301 basic medicine ,Sanger sequencing ,Cancer Research ,Mutation ,Nonsense mutation ,Biology ,medicine.disease ,medicine.disease_cause ,Frameshift mutation ,03 medical and health sciences ,symbols.namesake ,030104 developmental biology ,0302 clinical medicine ,Oncology ,Uterine cancer ,030220 oncology & carcinogenesis ,Carcinosarcoma ,medicine ,Cancer research ,symbols ,Exome ,Exome sequencing - Abstract
BACKGROUND Uterine carcinosarcomas (UCSs) are a rare but clinically aggressive form of cancer. They are biphasic tumors consisting of both epithelial and sarcomatous components. The majority of uterine carcinosarcomas are clonal, with the carcinomatous cells undergoing metaplasia to give rise to the sarcomatous component. The objective of the current study was to identify novel somatically mutated genes in UCSs. METHODS We whole exome sequenced paired tumor and nontumor DNAs from 14 UCSs and orthogonally validated 464 somatic variants using Sanger sequencing. Fifteen genes that were somatically mutated in at least 2 tumor exomes were Sanger sequenced in another 39 primary UCSs. RESULTS Overall, among 53 UCSs in the current study, the most frequently mutated of these 15 genes were tumor protein p53 (TP53) (75.5%), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) (34.0%), protein phosphatase 2, regulatory subunit A, alpha (PPP2R1A) (18.9%), F-box and WD repeat domain containing 7 (FBXW7) (18.9%), chromodomain helicase DNA binding protein 4 (CHD4) (17.0%), and forkhead box A2 (FOXA2) (15.1%). FOXA2 has not previously been implicated in UCSs and was predominated by frameshift and nonsense mutations. One UCS with a FOXA2 frameshift mutation expressed truncated FOXA2 protein by immunoblotting. Sequencing of FOXA2 in 160 primary endometrial carcinomas revealed somatic mutations in 5.7% of serous, 22.7% of clear cell, 9% of endometrioid, and 11.1% of mixed endometrial carcinomas, the majority of which were frameshift mutations. CONCLUSIONS Collectively, the findings of the current study provide compelling genetic evidence that FOXA2 is a pathogenic driver gene in the etiology of primary uterine cancers, including UCSs. Cancer 2017. © 2017 American Cancer Society.
- Published
- 2017
7. Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276)
- Author
-
Paul S. Meltzer, Adam R. Metwalli, Darmood Wei, W. Marston Linehan, Robert Worrell, Cathy D. Vocke, Hesed Padilla-Nash, Martin Lang, J. Keith Killian, Christopher J. Ricketts, Thomas Ried, Maria J. Merino, Carole Sourbier, Shawna L. Boyle, and Youfeng Yang
- Subjects
Male ,0301 basic medicine ,Cancer Research ,Karyotype ,Cell ,Chromophobe Renal Cell Carcinoma ,Mutation, Missense ,Mice, Nude ,Biology ,medicine.disease_cause ,Article ,Loss of heterozygosity ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Cell Line, Tumor ,Genetics ,medicine ,Carcinoma ,Animals ,Humans ,Carcinoma, Renal Cell ,Mutation ,Middle Aged ,medicine.disease ,Kidney Neoplasms ,030104 developmental biology ,medicine.anatomical_structure ,Cell culture ,030220 oncology & carcinogenesis ,Immunology ,Cancer research ,Tumor Suppressor Protein p53 ,Immortalised cell line - Abstract
Chromophobe renal cell carcinoma (ChRCC) represents 5% of all RCC cases and frequently demonstrates multiple chromosomal losses and an indolent pattern of local growth, but can demonstrate aggressive features and resistance to treatment in a metastatic setting. Cell line models are an important tool for the investigation of tumor biology and therapeutic drug efficacy. Currently, there are few ChRCC-derived cell lines and none is well characterized. This study characterizes a novel ChRCC-derived cell line model, UOK276. A large ChRCC tumor with regions of sarcomatoid differentiation was used to establish a spontaneously immortal cell line, UOK276. UOK276 was evaluated for chromosomal, mutational, and metabolic aberrations. The UOK276 cell line is hyperdiploid with a modal number of 49 chromosomes per cell, and evidence of copy-neutral loss of heterozygosity, as opposed to the classic pattern of ChRCC chromosomal losses. UOK276 demonstrated a TP53 missense mutation, expressed mutant TP53 protein, and responded to treatment with a small-molecule therapeutic agent, NSC319726, designed to reactivate mutated TP53. Xenograft tumors grew in nude mice and provide an in vivo animal model for the investigation of potential therapeutic regimes. The xenograft pathology and genetic analysis suggested that UOK276 was derived from the sarcomatoid region of the original tumor. In summary, UOK276 represents a novel in vitro and in vivo cell line model for aggressive, sarcomatoid-differentiated, TP53 mutant ChRCC. This preclinical model system could be used to investigate the novel biology of aggressive, sarcomatoid ChRCC and evaluate the new therapeutic regimes.
- Published
- 2017
8. Comparison of magnetic resonance imaging and ultrasound (MRI-US) fusion-guided prostate biopsies obtained from axial and sagittal approaches
- Author
-
Baris Turkbey, Peter A. Pinto, Nabeel Shakir, Cheng William Hong, Peter L. Choyke, Annerleim Walton-Diaz, Maria J. Merino, Bradford J. Wood, Arvin K. George, Daniel Su, and Soroush Rais-Bahrami
- Subjects
medicine.medical_specialty ,Prostate biopsy ,medicine.diagnostic_test ,business.industry ,Urology ,Ultrasound ,Cancer ,Magnetic resonance imaging ,medicine.disease ,Sagittal plane ,Prostate cancer ,medicine.anatomical_structure ,Prostate ,Biopsy ,medicine ,Radiology ,business - Abstract
Objective To compare cancer detection rates and concordance between magnetic resonance imaging and ultrasound (MRI-US) fusion-guided prostate biopsy cores obtained from axial and sagittal approaches. Patients and Methods Institutional records of MRI-US fusion-guided biopsy were reviewed. Detection rates for all cancers, Gleason ≥3 + 4 cancers, and Gleason ≥4 + 3 cancers were computed. Agreement between axial and sagittal cores for cancer detection, and frequency where one was upgraded the other was computed on a per-target and per-patient basis. Results In all, 893 encounters from 791 patients that underwent MRI-US fusion-guided biopsy in 2007–2013 were reviewed, yielding 4688 biopsy cores from 2344 targets for analysis. The mean age and PSA level at each encounter was 61.8 years and 9.7 ng/mL (median 6.45 ng/mL). Detection rates for all cancers, ≥3 + 4 cancers, and ≥4 + 3 cancers were 25.9%, 17.2%, and 8.1% for axial cores, and 26.1%, 17.6%, and 8.6% for sagittal cores. Per-target agreement was 88.6%, 93.0%, and 96.5%, respectively. On a per-target basis, the rates at which one core upgraded or detected a cancer missed on the other were 8.3% and 8.6% for axial and sagittal cores, respectively. Even with the inclusion of systematic biopsies, omission of axial or sagittal cores would have resulted in missed detection or under-characterisation of cancer in 4.7% or 5.2% of patients, respectively. Conclusion Cancer detection rates, Gleason scores, and core involvement from axial and sagittal cores are similar, but significant cancer may be missed if only one core is obtained for each target. Discordance between axial and sagittal cores is greatest in intermediate-risk scenarios, where obtaining multiple cores may improve tissue characterisation.
- Published
- 2014
9. Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies
- Author
-
Maria J. Merino, Anthony N. Hoang, Lambros Stamatakis, Baris Turkbey, Peter A. Pinto, Soroush Rais-Bahrami, M. Minhaj Siddiqui, Peter L. Choyke, Annerleim Walton-Diaz, Jeffrey W. Nix, Srinivas Vourganti, Ardeshir R. Rastinehad, Bradford J. Wood, Richard M. Simon, and Hong Truong
- Subjects
medicine.medical_specialty ,Prostate biopsy ,medicine.diagnostic_test ,business.industry ,Urology ,Area under the curve ,Magnetic resonance imaging ,Rectal examination ,urologic and male genital diseases ,medicine.disease ,Prostate cancer ,Prostate-specific antigen ,Prostate cancer screening ,Biopsy ,medicine ,business - Abstract
Objectives To determine the diagnostic yield of analysing biparametric (T2- and diffusion-weighted) magnetic resonance imaging (B-MRI) for prostate cancer detection compared with standard digital rectal examination (DRE) and prostate-specific antigen (PSA)-based screening. Patients and Methods Review of patients who were enrolled in a trial to undergo multiparametric-prostate (MP)-MRI and MR/ultrasound fusion-guided prostate biopsy at our institution identified 143 men who underwent MP-MRI in addition to standard DRE and PSA-based prostate cancer screening before any prostate biopsy. Patient demographics, DRE staging, PSA level, PSA density (PSAD), and B-MRI findings were assessed for association with prostate cancer detection on biopsy. Results Men with detected prostate cancer tended to be older, with a higher PSA level, higher PSAD, and more screen-positive lesions (SPL) on B-MRI. B-MRI performed well for the detection of prostate cancer with an area under the curve (AUC) of 0.80 (compared with 0.66 and 0.74 for PSA level and PSAD, respectively). We derived combined PSA and MRI-based formulas for detection of prostate cancer with optimised thresholds. (i) for PSA and B-MRI: PSA level + 6 x (the number of SPL) > 14 and (ii) for PSAD and B-MRI: 14 × (PSAD) + (the number of SPL) >4.25. AUC for equations 1 and 2 were 0.83 and 0.87 and overall accuracy of prostate cancer detection was 79% in both models. Conclusions The number of lesions positive on B-MRI outperforms PSA alone in detection of prostate cancer. Furthermore, this imaging criteria coupled as an adjunct with PSA level and PSAD, provides even more accuracy in detecting clinically significant prostate cancer.
- Published
- 2014
10. Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets
- Author
-
Maria J. Merino, Jeffrey Schlom, Caroline Jochems, Italia Grenga, Peter A. Pinto, James L. Gulley, Christopher R. Heery, Benedetto Farsaci, Jo A. Tucker, Ravi A. Madan, and Renee N. Donahue
- Subjects
Cancer Research ,Tumor-infiltrating lymphocytes ,business.industry ,chemical and pharmacologic phenomena ,hemic and immune systems ,Peripheral blood mononuclear cell ,Vaccination ,Immune system ,Oncology ,Antigen ,Immunology ,Medicine ,Cancer vaccine ,business ,Prostvac ,CD8 - Abstract
Preclinical studies have demonstrated that the combination of systemic subcutaneous (s.c.) vaccination with intratumoral (i.t.) vaccination was superior in the induction of antitumor activity vs. vaccination with either route alone. A subsequent phase I study employing i.t.-s.c. vaccination was carried out in men with locally recurrent or progressive prostate cancer. rF-PSA-TRICOM (PROSTVAC) vaccine was administered intraprostatically and rV-PSA-TRICOM followed by rF-PSA-TRICOM vaccine was administered systemically. In that study no dose limiting toxicities were observed, 19/21 patients had stable or improved prostate-specific antigen (PSA) values and tumor-infiltrating lymphocytes (TILs) increased in post- vs. pre-treatment tumor biopsies, analyzed employing conventional immunohistochemistry (IHC). In the studies reported here, 31 phenotypes of peripheral blood mononuclear cells (PBMCs) were analyzed prevaccination and postvaccination as well as the functions of PBMC regulatory T cells (Tregs) and natural killer cells. A trend was observed in decreases in serum PSA with the reduction of circulating Tregs postvaccination. Digital IHC was employed prevaccination and postvaccination to measure CD4 and CD8 TILs, as well as Treg TILs by conventional IHC. Few correlations were observed with CD4, CD8 or Treg in TILs vs. PBMCs. However, patients with lower levels of CD4 TILs prevaccination showed the greatest increases in CD4 TILs postvaccine, while Treg TILs decreased postvaccine. There was also a strong correlation between decreases in serum PSA and increases in CD8 TILs postvaccine. These studies provide additional rationale for the use of i.t.-s.c. vaccinations and demonstrate a noncoordinate expression of specific immune subsets in PBMCs vs. tumor.
- Published
- 2014
11. Decision support system for localizing prostate cancer based on multiparametric magnetic resonance imaging
- Author
-
Maria J. Merino, Baris Turkbey, Marcelino Bernardo, Vijay Shah, Yuxi Pang, Peter A. Pinto, Thomas J. Pohida, Haresh Mani, and Peter L. Choyke
- Subjects
Pathology ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Prostatectomy ,medicine.medical_treatment ,Cancer ,Magnetic resonance imaging ,General Medicine ,medicine.disease ,Prostate cancer ,Cohen's kappa ,medicine.anatomical_structure ,Prostate ,medicine ,Medical imaging ,Radiology ,business ,Multiparametric Magnetic Resonance Imaging - Abstract
Purpose: There is a growing need to localize prostate cancers on magnetic resonance imaging (MRI) to facilitate the use of image guided biopsy, focal therapy, and active surveillance follow up. Our goal was to develop a decision support system (DSS) for detecting and localizing peripheral zone prostate cancers by using machine learning approach to calculate a cancer probability map from multiparametric MR images (MP-MRI). Methods: This IRB approved Health Insurance Portability and Accountability Act compliant retrospective study consisted of 31 patients (mean age and serum prostate specific antigen of 60.4 and 6.62 ng/ml, respectively) who had MP-MRI at 3 T followed by radical prostatectomy. Seven patients were excluded due to technical issues with their MP-MRI (e.g., motion artifact, failure to perform all sequences). Cancer and normal regions were identified in the peripheral zone by correlating them to whole mount histology slides of the excised prostatectomy specimens. To facilitate the correlation, tissue blocks matching the MR slices were obtained using a MR-based patient-specific mold. Segmented regions on the MP-MRI were correlated to histopathology and used as training sets for the learning system that generated the cancer probability maps. Leave-one-patient-out cross-validation on the cancer and normal regions was performed to determine the learning system's efficacy, an evolutionary strategies approach (also known as a genetic algorithm) was used to find the optimal values for a set of parameters, and finally a cancer probability map was generated. Results: For the 24 patients that were used in the study, 225 cancer and 264 noncancerous regions were identified from the region maps. The efficacy of DSS was first determined without optimizing support vector machines (SVM) parameters, where a region having a cancer probability greater than or equal to 50% was considered as a correct classification. The nonoptimized system had an f-measure of 85% and the Kappa coefficient of 71% (Rater's agreement, where raters are DSS and ground truth histology). The efficacy of the DSS after optimizing SVM parameters using a genetic algorithm had an f-measure of 89% and a Kappa coefficient of 80%. Thus, after optimization of the DSS there was a 4% increase in the f-measure and a 9% increase in the Kappa coefficient. Conclusions: This DSS provides a cancer probability map for peripheral zone prostate tumors based on endorectal MP-MRI. These cancer probability maps can potentially aid radiologists in accuratelylocalizing peripheral zone prostate cancers for planning targeted biopsies, focal therapy, and follow up for active surveillance.
- Published
- 2012
12. Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell
- Author
-
Mitchell Ho, Jingli Zhang, Yunkai Yu, Liang Cao, Neetu Kalra, Raffit Hassan, and Maria J. Merino
- Subjects
Cancer Research ,Cell growth ,Growth factor ,medicine.medical_treatment ,Cell ,Cixutumumab ,Biology ,Molecular biology ,chemistry.chemical_compound ,medicine.anatomical_structure ,Oncology ,chemistry ,Cell culture ,medicine ,Growth inhibition ,Receptor ,Protein kinase B - Abstract
Insulin growth factor-I receptor (IGF-IR) is expressed in mesothelioma and therefore an attractive target for therapy. The antitumor activity of cixutumumab, a humanized monoclonal antibody to IGF-IR, in mesothelioma and relationship to IGF-IR expression was investigated using eight early passage tumor cells obtained from patients, nine established cell lines and an in vivo human mesothelioma tumor xenograft model. Although IGF-IR expression at the mRNA and protein level was present in all mesothelioma cells, using a quantitative ELISA immunoassay, there was considerable variability of IGF-IR expression ranging from 1 to 14 ng/mg of lysate. Using flow cytometry, the number of IGF-IR surface receptors varied from ≈ 2,000 to 50,000 sites/cell. Cells expressing >10,000 sites/cell had greater than 10% growth inhibition when treated with cixutumumab (100 μg/ml). Cixutumumab also induced antibody-dependent cell-mediated toxicity (>10% specific lysis) in cell lines, which had >20,000 IGF-IR sites/cell. Treatment with cixutumumab decreased phosphorylation of IGF-IR, Akt and Erk in cell lines, H226 and H28 having 24,000 and 51,000 IGF-IR sites/cell, respectively, but not in the cell line H2052 with 3,000 IGF-IR sites/cell. In vivo, cixutumumab treatment delayed growth of H226 mesothelioma tumor xenografts in mice and improved the overall survival of these mice compared to mice treated with saline (p < 0.004). Our results demonstrate that the antitumor efficacy of cixutumumab including inhibition of IGF-IR downstream signaling is highly correlated with IGF-IR sites/cell. A phase II clinical trial of cixutumumab is currently ongoing for the treatment of patients with mesothelioma.
- Published
- 2012
13. Metastatic pheochromocytoma: Does the size and age matter?
- Author
-
Dragana Milosevic, Tomáš Zelinka, Maria J. Merino, Jaroslava Dušková, Jiří Widimský, Zdeněk Musil, Deborah Burton, and Karel Pacak
- Subjects
medicine.medical_specialty ,Pathology ,Necrosis ,business.industry ,Incidence (epidemiology) ,Clinical Biochemistry ,Adrenal Gland Neoplasm ,Case-control study ,Retrospective cohort study ,General Medicine ,medicine.disease ,Malignancy ,Biochemistry ,Gastroenterology ,Pheochromocytoma ,Epinephrine ,Internal medicine ,medicine ,medicine.symptom ,business ,medicine.drug - Abstract
Eur J Clin Invest 2011; 41 (10): 1121–1128 Abstract Background Pheochromocytomas are tumours arising from chromaffin tissue located in the adrenal medulla associated with typical symptoms and signs which may occasionally develop metastases, which are defined as the presence of tumour cells at sites where these cells are not found. This retrospective analysis was focused on clinical, genetic and histopathologic characteristics of primary metastatic versus primary benign pheochromocytomas. Materials and methods We identified 41 subjects with metastatic pheochromocytoma and 108 subjects with apparently benign pheochromocytoma. We assessed dimension and biochemical profile of the primary tumour, age at presentation and time to develop metastases. Results Subjects with metastatic pheochromocytoma presented at a significantly younger age (41·4 ± 14·7 vs. 50·2 ± 13·7 years; P
- Published
- 2011
14. Noninvasive monitoring of a murine model of metastatic pheochromocytoma: A comparison of contrast-enhanced microCT and nonenhanced MRI
- Author
-
Richard Kvetnansky, Marcelino Bernardo, Peter L. Choyke, James F. Powers, Edwin W. Lai, Maria J. Merino, Daniel Schimel, Melanie Suzanne Kotys, Karel Pacak, J. Ruzicka, David Thomasson, and Lucia Martiniova
- Subjects
medicine.medical_specialty ,Lung Neoplasms ,X-ray microtomography ,Adrenal Gland Neoplasms ,Metastatic pheochromocytoma ,Contrast Media ,Mice, Nude ,Bone Neoplasms ,Pheochromocytoma ,Sensitivity and Specificity ,Article ,Mice ,Imaging, Three-Dimensional ,Liver Neoplasms, Experimental ,Animal model ,Image Processing, Computer-Assisted ,medicine ,Animals ,Radiology, Nuclear Medicine and imaging ,Monitoring, Physiologic ,medicine.diagnostic_test ,business.industry ,Magnetic resonance imaging ,X-Ray Microtomography ,Image Enhancement ,medicine.disease ,Magnetic Resonance Imaging ,Kidney Neoplasms ,Disease Models, Animal ,Murine model ,Dynamic contrast-enhanced MRI ,Female ,Radiology ,Tomography ,business - Abstract
Purpose To compare contrast-enhanced micro-computed tomography (microCT) and nonenhanced respiratory-triggered magnetic resonance imaging (MRI) in an animal model of metastatic pheochromocytoma. Animal models are becoming important in the study of cancer treatment and imaging is useful in minimizing the number of animals needed and reducing costs associated with autopsies. However, the choice of imaging modality is still evolving. Materials and Methods Adult female nude mice were injected by tail vein with a mouse pheochromocytoma (MPC) cell line (MPC 4/30PRR) to create a metastatic model. After optimizing imaging techniques, eight mice were imaged with both respiratory triggered MRI and microCT and the findings were verified histologically. Results MicroCT and MRI were approximately equal in their ability to detect hepatic metastases at a size threshold of 350 μm. In the lungs, MRI was more sensitive than microCT, detecting lesions 0.6 mm in diameter versus 1 mm for microCT. Additionally, MRI was more sensitive for lesions in the kidneys, bone, ovaries, and adrenal glands. MRI demonstrated a higher contrast-to-noise ratio (CNR) than microCT. Conclusion In addition to the advantage of not exposing the animal to ionizing radiation, MRI provided a more complete assessment of the extent of metastases in this model compared to microCT. J. Magn. Reson. Imaging 2009;29:685–691. © 2009 Wiley-Liss, Inc.
- Published
- 2009
15. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine
- Author
-
Karel Pacak, Seth M. Steinberg, Steven D. Averbuch, Elizabeth Hung, Hui Huang, Maria J. Merino, Jame Abraham, and Tito Fojo
- Subjects
Adult ,Male ,Cancer Research ,Vincristine ,medicine.medical_specialty ,Adolescent ,Cyclophosphamide ,Dacarbazine ,Adrenal Gland Neoplasms ,Urology ,Kaplan-Meier Estimate ,Pheochromocytoma ,Article ,Paraganglioma ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Medicine ,Child ,business.industry ,Cancer ,Combination chemotherapy ,Middle Aged ,medicine.disease ,Surgery ,Treatment Outcome ,Oncology ,Female ,business ,Progressive disease ,Follow-Up Studies ,medicine.drug - Abstract
BACKGROUND A long-term follow-up was conducted of 18 patients with a diagnosis of pheochromocytoma/paraganglioma treated with a combination of cyclophosphamide, vincristine, and dacarbazine (CVD). METHODS The study design was a nonrandomized, single-arm trial conducted at a government medical referral center. Eighteen patients with metastatic malignant pheochromocytoma/paraganglioma were studied. After controlling symptoms of catecholamine excess, patients were treated with cyclophosphamide at 750 mg/m2, vincristine at 1.4 mg/m2, and dacarbazine at 600 mg/m2 on Day 1 and dacarbazine at 600 mg/m2 on Day 2, every 21 to 28 days. RESULTS Combination chemotherapy with CVD produced a complete response rate of 11% and a partial response rate of 44%. Median survival from a landmark was 3.8 years for patients whose tumors responded to therapy and 1.8 years for patients whose tumors did not respond (P = .65). All patients with tumors scored as responding reported improvement in their symptoms related to excessive catecholamine release and had objective improvements in blood pressure. CVD was well tolerated with only grade I/II toxicities. CONCLUSIONS Combination chemotherapy with CVD produced objective tumor responses in patients with advanced malignant pheochromocytoma/paraganglioma. In this 22-year follow-up there was no difference in overall survival between patients whose tumors objectively shrank and those with stable or progressive disease. However, patients reported improvement in symptoms, had objective improvements in blood pressure, and had tumor shrinkage that made surgical resection possible. The authors conclude that CVD therapy is not indicated in every patient with metastatic pheochromocytoma/paraganglioma, but should be considered in the management of patients with symptoms and where tumor shrinkage might be beneficial. Cancer 2008. © 2008 American Cancer Society.
- Published
- 2008
16. Identification of a unique epigenetic sub-microenvironment in prostate cancer
- Author
-
Steven K. Libutti, Paul S. Albert, John W. Gillespie, Heidi S. Erickson, Michael R. Emmert-Buck, Jaime Rodriguez-Canales, W. M. Linehan, Rodrigo F. Chuaqui, Peter A. Pinto, Annely M. Richardson, Karen Woodson, Maria J. Merino, Benjamin S Wallis, Michael A. Tangrea, and Jeffrey C. Hanson
- Subjects
Male ,Cell type ,Pathology ,medicine.medical_specialty ,Stromal cell ,Prostatic Hyperplasia ,Biology ,Methylation ,Epithelium ,Epigenesis, Genetic ,Pathology and Forensic Medicine ,Prostate cancer ,Prostate ,medicine ,Humans ,Epigenetics ,Promoter Regions, Genetic ,Base Sequence ,Prostatic Neoplasms ,Cancer ,medicine.disease ,medicine.anatomical_structure ,Glutathione S-Transferase pi ,Cancer research ,CpG Islands ,Stromal Cells ,Microdissection - Abstract
The glutathione S-transferase P1 (GSTP1) gene promoter is methylated in tumour cells in more than 90% of prostate carcinomas. Recently, GSTP1 promoter methylation was identified in tumour-associated stromal cells in addition to the tumour epithelium. To define the extent and location of stromal methylation, epigenetic mapping using pyrosequencing quantification of GSTP1 promoter methylation and an anatomical three-dimensional reconstruction of an entire human prostate specimen with cancer were performed. Normal epithelium and stroma, tumour epithelium, and tumour-associated stromal cells were laser capture-microdissected from multiple locations throughout the gland. As expected, the GSTP1 promoter in both normal epithelium and normal stromal cells distant from the tumour was not methylated and the tumour epithelium showed consistently high levels of promoter methylation throughout. However, tumour-associated stromal cells were found to be methylated only in a localized and distinct anatomical sub-field of the tumour, revealing the presence of an epigenetically unique microenvironment within the cancer. Morphologically, the sub-field consisted of typical, non-reactive stroma, representing a genomic alteration in cells that appeared otherwise histologically normal. Similar epigenetic anatomical mapping of a control prostate gland without cancer showed low background methylation levels in all cell types throughout the specimen. These data suggest that stromal cell methylation can occur in a distinct sub-region of prostate cancer and may have implications for understanding tumour biology and clinical intervention.
- Published
- 2007
17. Intracystic papillary carcinoma of the breast after mastectomy, radiotherapy or excisional biopsy alone
- Author
-
Darryl Carter, Maria J. Merino, and Samuel L. Orr
- Subjects
Cancer Research ,medicine.medical_specialty ,Pathology ,Intracystic papillary carcinoma ,Invasive carcinoma ,Axillary lymph nodes ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,medicine.disease ,Radiation therapy ,medicine.anatomical_structure ,Oncology ,parasitic diseases ,Biopsy ,medicine ,Carcinoma ,Papillary pattern ,cardiovascular diseases ,Radiology ,business ,Mastectomy - Abstract
Intracystic papillary carcinoma of the breast (IPC) was distinguished from the more common papillary intraductal carcinoma (DCIS) and infiltrating duct carcinoma with a papillary pattern. IPC was defined as a solitary tumor with a pattern recognizable as carcinoma which is confined to a dilated duct. A series of 41 such cases was collected from three institutions. Twenty-nine patients underwent mastectomy; 11 of them had axillary dissections. None of these patients had metastatic disease in the axillary lymph nodes or recurrence in the follow-up period which averaged five years. Eleven patients did not have mastectomy or radiotherapy. Eight of these patients (followed for an average of ten years) had no recurrence. The only patients who developed invasive carcinoma were those with DCIS as well as IPC in the excisional biopsy. The data suggest that IPC is much more likely to be cured by local treatment than is IPC accompanied by DCIS.
- Published
- 2006
18. A Phase I study of infusional vinblastine in combination with the p-glycoprotein antagonist PSC 833 (valspodar)
- Author
-
Peter L. Choyke, Beverly Meadows, Raymond C. Bergan, Barry R. Goldspiel, Clara C. Chen, Robert W. Robey, Tito Fojo, Thomas M. Smith, Isagani Chico, Susan Bakke, Susan E. Bates, Maria J. Merino, William D. Figg, and Min H. Kang
- Subjects
Cancer Research ,Chemotherapy ,business.industry ,medicine.medical_treatment ,Neutropenia ,Pharmacology ,medicine.disease ,Vinblastine ,Bioavailability ,chemistry.chemical_compound ,Oncology ,Pharmacokinetics ,chemistry ,Oral administration ,Toxicity ,medicine ,Valspodar ,business ,medicine.drug - Abstract
BACKGROUND PSC 833 is a second-generation P-glycoprotein (Pgp) antagonist developed to reverse multidrug resistance (MDR). The authors conducted a Phase I study of orally administered PSC 833 in combination with vinblastine administered as a 5-day continuous infusion. METHODS Seventy-nine patients with advanced malignant disease were enrolled in the trial and treated with escalating doses of PSC 833. Pharmacokinetic interactions between PSC 833 and vinblastine were anticipated. Accordingly, when dose limiting toxicities were observed, the dose of vinblastine was reduced as PSC 833 was escalated. Three schedules and two formulations of PSC 833 were used in the study. RESULTS The maximum tolerated doses of PSC 833 were 12.5 mg/kg orally every 12 hours for 8 days for the liquid formulation in combination with 0.9 mg/m2 per day vinblastine as a continuous intravenous infusion (CIV) for 5 days; and 4 mg/kg orally every 6 hours for 8 days for the microemulsion formulation in combination with 0.6 mg/m2 per day vinblastine CIV for 5 days. The principal toxicities for PSC 833 were ataxia and paresthesias and for the combination, constipation, fever. and neutropenia. Increased oral bioavailability and increased peak and trough concentrations were observed with the microemulsion formulation. Significant interpatient variability in pharmacokinetic parameters was observed. Ten patients studied at the MTD for PSC 833 (4 mg/kg orally every 6 hours for 8 days) had inhibition of rhodamine efflux from CD56 positive peripheral lymphocytes as a surrogate for Pgp antagonism. Among 43 evaluable patients with clear cell carcinoma of the kidney, 3 patients had complete responses, and 1 patient had a partial response. CONCLUSIONS PSC 833 in combination with vinblastine can be administered safely to patients provided the vinblastine dose is adjusted for pharmacokinetic interactions. The high interpatient variability is a significant confounding factor. Surrogate studies with CD56 positive cells suggest that Pgp inhibition in the clinical setting is achievable. Improved methods for predicting pharmacokinetic interactions should improve future studies. Cancer 2001;92:1577–90. © 2001 American Cancer Society.
- Published
- 2001
19. Detection of loss of heterozygosity at chromosome 3p25-26 in primary and metastatic ovarian clear-cell carcinoma: Utilization of microdissection and polymerase chain reaction in archival tissues
- Author
-
Andrea Abati, W. Marston Linehan, Diana Palacios, Aylin Simsir, and Maria J. Merino
- Subjects
Pathology ,medicine.medical_specialty ,Histology ,endocrine system diseases ,Ubiquitin-Protein Ligases ,Loss of Heterozygosity ,Locus (genetics) ,Biology ,Polymerase Chain Reaction ,Pathology and Forensic Medicine ,Metastasis ,law.invention ,Diagnosis, Differential ,Ligases ,Loss of heterozygosity ,law ,Ovarian carcinoma ,Biomarkers, Tumor ,medicine ,Humans ,Genes, Tumor Suppressor ,neoplasms ,Microdissection ,Polymerase chain reaction ,Retrospective Studies ,Ovarian Neoplasms ,Dissection ,Tumor Suppressor Proteins ,Proteins ,General Medicine ,medicine.disease ,female genital diseases and pregnancy complications ,Chromosome 3 ,Von Hippel-Lindau Tumor Suppressor Protein ,Clear cell carcinoma ,Female ,Chromosomes, Human, Pair 3 ,Adenocarcinoma, Clear Cell - Abstract
Loss of heterozygosity (LOH) at the 3p region is found in up to 50% of epithelial ovarian neoplasms. The von Hippel-Lindau (VHL) gene at the 3p25 locus is one of the tumor-suppressor genes located at 3p. The role, if any, of the VHL gene locus is not clear in ovarian carcinogenesis. We analyzed primary and metastatic ovarian clear-cell carcinomas (OCCC) for LOH at 3p25 to determine its frequency and its diagnostic utility as an adjunctive tool in the differential diagnosis of metastatic clear-cell carcinomas. Microdissection followed by single-step DNA extraction and polymerase chain reaction (PCR) amplification, using two polymorphic markers flanking the VHL gene locus, was done on archival histology and cytology samples from 9 patients with metastatic OCCC. Of the informative cases, 43% of the metastatic and 50% of the primary OCCC showed LOH. LOH at the VHL gene locus is not uncommon in clear-cell ovarian carcinoma. LOH at 3p25 in cytologic specimens may be a valuable adjunct in the diagnosis of OCCC metastasis in cytologically equivocal cases. OCCC should enter the differential in clear-cell carcinomas of unknown primary that show LOH at 3p25. Diagn. Cytopathol. 24:328–332, 2001. Published 2001 Wiley-Liss, Inc.
- Published
- 2001
20. The tall cell variant of papillary carcinoma of the thyroid
- Author
-
Maria J. Merino, Armando C. Filie, R M T Bonita Bryant, Andrea Abati, Andres Chiesa, and Mark E. Sobel
- Subjects
Cancer Research ,Pathology ,medicine.medical_specialty ,Thyroid ,Cytogenetics ,Cancer ,Biology ,medicine.disease ,Metastasis ,Loss of heterozygosity ,medicine.anatomical_structure ,Oncology ,Cytopathology ,Cytology ,medicine ,Microdissection - Abstract
BACKGROUND The Tall cell variant of papillary carcinoma of the thyroid (TCV) is characterized by the proliferation of oxyphilic, tall, columnar cells with a height-to-width ratio of at least 2:1. TCV exhibits more aggressive clinical behavior than conventional thyroid papillary carcinoma (CPC). Cytologic features suggestive of TCV have been described in fine-needle aspiration material from primary tumors. Similarly, loss of heterozygosity (LOH) for chromosome 1 (D1S243) and the p53 gene (TP53) have been reported in TCV but not in CPC, thus making exploitation of this genetic feature a potential tool for molecular discrimination between these two neoplasms. METHODS Cytology samples of metastatic and/or recurrent neoplasms (M/R) (12 cases) and 7 cases of primary TCV obtained from 12 patients were evaluated. The cytologic findings of these cases were compared with previously published findings. Microdissection and polymerase chain reaction for LOH for chromosome 1 and p53 (D1S243 and TP53 markers) were performed on cytologic smears from 6 cases of M/R tumors and 3 cases of primary tumors. RESULTS More then 50% of M/R showed atypical follicular cells with enlarged nuclei, granular chromatin, nuclear grooves, pseudoinclusions, and abundant finely granular cytoplasm. Cells were disposed in monolayers (58%) and papillary clusters (50%). Similar findings were present in cases of primary TCV. LOH studies showed that 4 of 6 M/R were noninformative and 2 of 3 cases of primary TCV were informative for the D1S243 marker; however, in contrast with previously published reports, no LOH was detected for the markers evaluated. CONCLUSIONS M/R and primary TCV have similar cytologic features. Additional studies of larger series of M/R and primary TCV should be performed to delineate further any potential application of LOH for chromosome 1 and the p53 gene as a tool for diagnosing TCV with cytologic preparations. Cancer (Cancer Cytopathol) 1999;87:238–42. © 1999 American Cancer Society.
- Published
- 1999
21. Male adnexal tumour of probable Wolffian origin occurring in a seminal vesicle
- Author
-
Jae Y. Ro, S. M. Popok, Lavinia P. Middleton, Alberto G. Ayala, Nelson G. Ordóñez, and Maria J. Merino
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,Histology ,Vimentin ,Tubular Pattern ,S100 protein ,Pathology and Forensic Medicine ,Immunoenzyme Techniques ,Cytokeratin ,Seminal vesicle ,Biomarkers, Tumor ,medicine ,Humans ,biology ,Genitourinary system ,Seminal Vesicles ,General Medicine ,Anatomy ,Microscopy, Electron ,medicine.anatomical_structure ,Urinary Bladder Neoplasms ,Adnexal Diseases ,Mesonephros ,Genital Neoplasms, Male ,biology.protein ,Immunohistochemistry ,Female ,Neoplasm Recurrence, Local ,Differential diagnosis - Abstract
Aims: Adnexal tumours of probable Wolffian origin are rare low-grade malignant neoplasms that have been previously described in the broad ligament, ovaries and retroperitoneum of females. All are characterized by small, bland epithelial cells growing in a diffuse, trabecular, or tubular pattern. The majority of the cases reported have pursued a benign clinical course. However, recurrences and distant metastases have been described. We present a case of a male adnexal tumour of probable Wolffian origin occurring in the left seminal vesicle of a 29-year-old man with 23 years of follow-up. Results The diagnosis is supported by immunohistochemical and electron microscopic findings: The tumour cells were immunoreactive for cytokeratin and vimentin while smooth muscle antigen and S100 protein were uniformly negative. By electron microscopy cells were arranged in an acinar pattern and surrounded flocculent, electron-dense material. Individual cells contained numerous dense bodies and free ribrosomes. The patient had recurrences at 14 and 23 years after initial diagnosis. Conclusion This is the first report of this entity in a male. The literature on this unusual tumour is reviewed and the clinicopathological, immunohistochemical and ultrastructural features are described. The differential diagnosis of this seemingly indolent tumour is discussed with genitourinary tumours having a more aggressive clinical course.
- Published
- 1998
22. Immunohistochemical expression of ?-class glutathioneS-transferase is down-regulated in adenocarcinoma of the prostate
- Author
-
Paul H. Duray, Christopher A. Moskaluk, Maria J. Merino, Kenneth H. Cowan, and Marston Linehan
- Subjects
Cancer Research ,Pathology ,medicine.medical_specialty ,Adenoma ,Cancer ,Biology ,medicine.disease ,medicine.disease_cause ,Malignant transformation ,medicine.anatomical_structure ,Oncology ,Prostate ,medicine ,Immunohistochemistry ,Adenocarcinoma ,High-grade prostatic intraepithelial neoplasia ,Carcinogenesis - Abstract
BACKGROUND Glutathione S-transferase is often up-regulated in neoplastic tissues. A single previous study found a loss of expression associated with carcinogenesis of the prostate. METHODS To extend these results, the authors performed immunohistochemical staining for the π-class of glutathione S-transferase (GSTπ) on 74 archival sequential prostate specimens. The antibody used was derived from rabbits immunized against purified human GSTπ. Paraffin blocks containing both benign tissue and adenocarcinoma were studied. RESULTS Heterogeneous expression of GSTπ in benign acini was found in 96% of cases, but GSTπ was not expressed in 95% of invasive adenocarcinomas of the prostate, nor was it expressed in any of the foci of high grade prostatic intraepithelial neoplasia. Basal cells of benign acini showed strong, diffuse staining for GSTπ, whereas the secretory luminal epithelium expressed GSTπ weakly and focally. CONCLUSIONS This study confirms the down-regulation of GSTπ in adenocarcinoma of the prostate and shows that the loss of GSTπ expression is a phenotype associated with malignant transformation. Cancer 1997; 79:1595-9. © 1997 American Cancer Society.
- Published
- 1997
23. Small cell carcinoma of the endometrium with associated ocular paraneoplastic syndrome
- Author
-
Elias Campo, Miguel N. Buunier, and Maria J. Merino
- Subjects
Cancer Research ,Pathology ,medicine.medical_specialty ,Lung ,business.industry ,Cell ,Uterus ,Tumor cells ,Endometrium ,medicine.disease ,Oat cell carcinoma ,Small-cell carcinoma ,medicine.anatomical_structure ,Oncology ,medicine ,business ,Hormone - Abstract
Small cell carcinomas are well-recognized tumors known to occur predominantly in the lung. These neoplasms occasionally are associated with a variety of symptoms caused by hormones and other products produced by the tumor cells (paraneoplastic syndromes). However, in the gynecologic tract such neoplasms are extremely rare. The authors report the case of an elderly woman who presented with visual disturbances caused by a primary small cell carcinoma of the uterus.
- Published
- 1992
24. Signet ring carcinoma of the female breast: A clinicopathologic analysis of 24 cases
- Author
-
Maria J. Merino and Virginia A. LiVolsi
- Subjects
Cancer Research ,Poor prognosis ,Pathology ,medicine.medical_specialty ,Signet ring cell ,business.industry ,Mucin ,Lobular carcinoma ,Signet ring carcinoma ,Retroperitoneal fibrosis ,medicine.disease ,digestive system diseases ,Breast cancer ,Oncology ,Gastrointestinal disease ,medicine ,medicine.symptom ,skin and connective tissue diseases ,business - Abstract
Signet ring carcinomas of the breast have been separated recently as an aggressive subtype of breast cancer, distinct from mucinous (colloid) carcinomas. Twenty-four cases of signet ring breast cancer (2% of total breast cancers at the authors' institution) were analyzed. The authors' study indicates that histogenetically such lesions are derived from lobular, not ductal, cells since mucin patterns and ultrastructural features are shared. In addition, in each of our 24 cases, infiltrating lobular carcinoma was identified; in 11 of these (46%) lobular carcinoma in-situ (LCIS) was also noted. Signet ring carcinomas show an unusual metastatic pattern with a propensity to involve serosal surfaces and mimicking gastrointestinal disease or retroperitoneal fibrosis. These tumors are associated with a poor prognosis, with 60% of our 24 patients dead of disease at 7 years. The distinctive clinical and pathologic features of signet ring carcinoma warrant separation of this group of tumors from other forms of breast cancer.
- Published
- 1981
25. Malignant carotid body tumors: Report of two cases and review of the literature
- Author
-
Virginia A. LiVolsi and Maria J. Merino
- Subjects
Cancer Research ,Pathology ,medicine.medical_specialty ,business.industry ,medicine.disease ,Malignancy ,Glomus jugulare ,medicine.anatomical_structure ,Oncology ,Carotid Body Tumors ,Medicine ,Neoplasm ,Carotid body ,business - Abstract
Paragangliomas may arise in any area of the body where nonchromaffin paraganglia are situated. These include the glomus jugulare, the carotid body, and the retroperitoneum. Malignant behavior of these paragangliomas has been a controversial subject with most authors, who consider them to be benign tumors. Some authors have diagnosed locally recurrent and infiltrative tumors as malignant, whereas most require the demonstration of metastatic potential as the only criterion for malignancy. Two cases of metastasizing carotid body tumors are reported with a review of the literature on this unusual neoplasm.
- Published
- 1981
26. The rapid onset of cutaneous angiosarcoma after radiotherapy for breast carcinoma
- Author
-
Christopher N. Otis, Richard E. Peschel, Maria J. Merino, Paul H. Duray, and Charles McKhann
- Subjects
Cancer Research ,Pathology ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,medicine.disease ,Radiation therapy ,Hemangiosarcoma ,Oncology ,medicine ,Carcinoma ,Osteosarcoma ,Angiosarcoma ,Chondrosarcoma ,Breast carcinoma ,business ,neoplasms ,Mastectomy - Abstract
Malignant neoplasms known to develop following external beam radiation include squamous cell carcinoma, osteosarcoma, chondrosarcoma, malignant fibrous histiocytoma, mixed mullerian tumors, malignant schwannoma, myelogenous leukemia and angiosarcoma. Latency periods of many years characterize the onset of these tumors following the exposure. Cutaneous angiosarcoma following radiotherapy for breast carcinoma has been rarely documented, occurring up to 13 years postirradiation. Two cases of this entity are reported occurring 37 months postradiotherapy at the site of mastectomy performed for mammary duct carcinoma.
- Published
- 1986
27. Exogenous hormone use and fibrocystic breast disease by histopathologic component
- Author
-
Sharon I. Ort, Colin White, Theodore R. Holford, Jennifer L. Kelsey, Maria J. Merino, Theresa Z. O'Connor, Gertrud S. Berkowitz, Virginia A. LiVolsi, and Nancy G. Hildreth
- Subjects
Adult ,Risk ,Aging ,Cancer Research ,medicine.medical_specialty ,Fibrocystic Breast Disease ,medicine.drug_class ,Biopsy ,Mammary gland ,Population ,Physiology ,Papillomatosis ,Epithelium ,Sampling Studies ,Contraceptives, Oral, Hormonal ,Estradiol Congeners ,medicine ,Humans ,Breast ,Risk factor ,education ,Aged ,Gynecology ,education.field_of_study ,medicine.diagnostic_test ,business.industry ,Middle Aged ,medicine.disease ,Menopause ,medicine.anatomical_structure ,Oncology ,Estrogen ,Female ,medicine.symptom ,business ,Contraceptives, Oral - Abstract
In a hospital-based case-control study of 590 women with biopsy-proven fibrocystic breast disease and 1,018 control women with other surgical conditions, no linear relationship was evident between the use of oral contraceptives or of estrogen replacement therapy and the degree of epithelial atypia of the fibrocystic lesions. Case-control and intracase comparisons suggested that oral contraceptive use might be associated with an increased occurrence of sclerosing adenosis among the premenopausal women and of gross cysts among the postmenopausal women. Estrogen replacement therapy, which was positively associated with fibrocystic breast disease as a whole among the post-menopausal women, was most frequently used among the cases whose biopsy specimens exhibited gross cysts, papillomatosis or papillary hyperplasia.
- Published
- 1984
28. A clinical and histopathologic analysis of the results of conservation surgery and radiation therapy in stage I and II breast carcinoma
- Author
-
Leonard R. Prosnitz, Paul V. Hartman, Charles McKhann, Joseph B. Weissberg, Timothy P. Mate, Darryl Carter, Diana B. Fischer, and Maria J. Merino
- Subjects
Cancer Research ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Mammary gland ,Perineural invasion ,medicine.disease ,Surgery ,Radiation therapy ,medicine.anatomical_structure ,Oncology ,medicine ,Carcinoma ,Stage (cooking) ,business ,Breast carcinoma ,Survival rate ,Mastectomy - Abstract
One hundred eighty women with clinical Stage I or II operable breast carcinoma were treated by radiotherapy following local tumor excision at Yale-New Haven Hospital through 1980. With a median follow-up time of 6.9 years, the actuarial 5-year overall and disease-free survival rates were 82% and 78%, respectively. The 5-year actuarial breast-recurrence-free survival rate was 92%. Several clinical-histopathologic features and treatment parameters were assessed for their significance as predictors of local breast failure or distant relapse. Cox lifetable regression analysis showed that patients with clinical Stage II carcinomas had significantly worse overall and relapse-free survival rates, but clinical stage alone had no effect on the rate of breast recurrence. Furthermore, a decrease in overall and disease-free survival was evident when necrosis was present in the tumor or when patients had an infiltrating lobular carcinoma. Breast recurrence-free survival was also influenced adversely by the presence of these two tumor features, especially when either tumor necrosis or infiltrating lobular carcinoma was found in conjunction with clinical Stage II lesions. Other histologic features such as grade, vascular invasion, perineural invasion, or the presence of an intraductal component of carcinoma did not affect outcome, nor did the treatment techniques employed appear to have a differential effect.
- Published
- 1986
29. Oncocytomas of the kidney
- Author
-
Virginia A. LiVolsi and Maria J. Merino
- Subjects
Cancer Research ,Pathology ,medicine.medical_specialty ,Kidney ,Necrosis ,Tumor size ,business.industry ,Asymptomatic ,Lesion ,medicine.anatomical_structure ,Oncology ,Eosinophilic ,medicine ,Recurrent disease ,Granular cytoplasm ,medicine.symptom ,business - Abstract
Fourteen cases of renal oncocytomas are presented. By definition these lesions are composed entirely of pink eosinophilic cells with abundant granular cytoplasm. No evidence of mitotic activity or necrosis was seen in any of the cases, although focal areas of nuclear pleomorphism were identified in two cases. Clinically the patients have remained asymptomatic and without evidence of metastatic or recurrent disease in a follow-up that ranges from 1-14 years. The clinical behavior of these tumors favors the benign nature of the lesion regardless of the tumor size.
- Published
- 1982
30. Uterine papillary serous carcinoma
- Author
-
Ernest I. Kohorn, Joseph T. Chambers, and Maria J. Merino
- Subjects
Chemotherapy ,medicine.medical_specialty ,Hysterectomy ,Lymphovascular invasion ,business.industry ,medicine.medical_treatment ,Uterus ,Obstetrics and Gynecology ,Combination chemotherapy ,General Medicine ,medicine.disease ,Surgery ,Radiation therapy ,medicine.anatomical_structure ,medicine ,Stage (cooking) ,business ,Progressive disease - Abstract
Reviewed are 37 patients with the diagnosis of uterine papillary serous carcinoma. Clinically, 19 patients presented as stage I, 9 as stage II, 1 as stage III, and 8 as stage IV. Four of 18 patients with clinical stage I disease who underwent surgery had pelvic metastases and five had disease spread beyond the pelvis. Three of nine clinical stage II patients had intraabdominal metastases. At least 50% myometrial invasion was found in 43% of the 30 hysterectomy specimens, and lymphatic invasion in the myometrium was demonstrated in 78% of the specimens. Each of the 15 patients with surgical stage I or II disease received local radiation therapy: 10 are alive and of these 9 are disease-free. Each of nine clinical stage II patients received intense radiation therapy and hysterectomy; seven are alive and of these four are disease free. The five-year survival for combined surgical stages I and II patients was 45%. The three-year survival for combined surgical stages III and IV was 11%. Thirteen patients have been treated with combination chemotherapy, 11 with cis-platinum-based combinations. Nine of these patients are dead; four are alive, with three of these having progressive disease.
- Published
- 1987
31. Are cytosol estrogen and progestin receptors of prognostic significance in the management of epithelial ovarian cancer?
- Author
-
N MacLusky, Peter E. Schwartz, and Maria J. Merino
- Subjects
Oncology ,medicine.medical_specialty ,animal structures ,medicine.drug_class ,business.industry ,Obstetrics and Gynecology ,Estrogen receptor ,Improved survival ,Patient survival ,General Medicine ,Cytosol ,Estrogen ,Internal medicine ,polycyclic compounds ,medicine ,Cancer research ,Epithelial ovarian cancer ,Receptor ,business ,Progestin ,hormones, hormone substitutes, and hormone antagonists - Abstract
Cystosol estrogen and progestin receptor levels in tumor samples from 101 patients with previously untreated primary epithelial ovarian cancers were correlated with patient survival. Patients with stage I and II disease whose tumors contained elevated levels of cytosol progestin receptors had an improved survival over patients with tumors containing low levels of cytosol progestin receptors. However, patients with advanced ovarian cancers and low cytosol progestin receptors had significantly longer survival. The four-year estimated duration of survival with advanced disease and cytosol progestin receptors less than seven was 82%, whereas if the cytosol progestin receptors were seven or more, the four-year estimated duration of survival was only 10%. The explanation for this dichotomy is not evident at this time. In this study cytosol estrogen receptor levels were not associated with survival. These results suggest that measurement of cytosol progestin receptors is of prognostic value in advanced epithelial ovarian cancers.
- Published
- 1987
32. Borderline ovarian tumors
- Author
-
Peter E. Schwartz, Maria J. Merino, Ernest I. Kohorn, and Joseph T. Chambers
- Subjects
Adult ,Reoperation ,Melphalan ,medicine.medical_specialty ,Adolescent ,Combination therapy ,Ovariectomy ,Urology ,Antineoplastic Agents ,Hysterectomy ,Pregnancy ,medicine ,Adjuvant therapy ,Humans ,Antigens, Tumor-Associated, Carbohydrate ,Stage IIIC ,Stage (cooking) ,Survival rate ,Aged ,Neoplasm Staging ,Aged, 80 and over ,Ovarian Neoplasms ,business.industry ,Obstetrics and Gynecology ,Cancer ,Combination chemotherapy ,General Medicine ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,Surgery ,Female ,Neoplasm Recurrence, Local ,Ovarian cancer ,business ,Follow-Up Studies ,medicine.drug - Abstract
Ninety-four patients with borderline ovarian tumors were retrospectively analyzed for clinical features, treatments, and survival characteristics. There were 46 patients with FIG0 stage IA cancer, 7 with stage IB, 20 with stage IC, 4 with stage IIB, 5 with stage IIC, 5 with stage IIIA, 3 with stage 1118, and 4 with stage IIIC tumors. Seventy patients had at-least a total abdominal hysterectomy and bilateral salpingo-oophorectomy, 20 patients had conservative surgery including unitateral salpingo-oophorectomy or ovarian cystectomy, and 4 patients had bilateral salpingo-oophorectomy. Fifteen patients with stage I disease received adjuvant melphalan therapy and 2 received external beam radiation for concomitant gynecologic cancers; 7 with stage II tumors received adjuvant melphalan therapy and 1 received external beam radiation; and 5 with staga Ill tumors received melphalan therapy and 6 patients received cisplatin-based combination chemotherapy. Follow-up ranged from 1 to 117 months, with a median of 33.5 months. Eighty-seven patients were alive. Seven patients died, two of disease. The overall 5-year survival rate was 83.0%; those treated with adjuvant therapy had a 79.5% survival, whereas the others had 64.6% survival. Second-look surgery was performed in 10 patients; six results were negative after melphalan therapy, one was negative after cisplatin combination therapy, and one was negative after no adjuvant treatment. Two patients had positlve second-look surgery, one with stage IIIC disease treated with a cisplatin combination and the other with stage IC disease treated with melphalan. This review did not demonstrate that patients with borderline ovarian tumors benefited from adjuvant therapy. (AM J OBSTET GYNECOL 1988;159:1088-94.)
- Published
- 1989
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.